Divis Laboratories Ltd Share Price – NSE /  BSE

Pharmaceuticals, Mid Cap

Divis Laboratories Ltd is up for a third straight session today. The stock is quoting at Rs 6742, up 1.02% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.42% on the day, quoting at 25209.65. The Sensex is at 82725.53, up 0.41%. Divis Laboratories Ltd has gained around 13.46% in last one month.

Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has gained around 4.53% in last one month and is currently quoting at 21948, up 0.51% on the day. The volume in the stock stood at 3.53 lakh shares today, compared to the daily average of 5.77 lakh shares in last one month.

The benchmark June futures contract for the stock is quoting at Rs 6761, up 0.86% on the day. Divis Laboratories Ltd is up 51.43% in last one year as compared to a 8.09% jump in NIFTY and a 11.76% jump in the Nifty Pharma index.

The PE of the stock is 80.18 based on TTM earnings ending March 25.

Powered by Capital Market - Live News

Divis Laboratories Ltd is down for a fifth straight session today. The stock is quoting at Rs 6571, down 0.62% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.16% on the day, quoting at 24710.35. The Sensex is at 81322.01, down 0.16%.Divis Laboratories Ltd has added around 7.29% in last one month.Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has eased around 1.74% in last one month and is currently quoting at 21442.05, down 0.21% on the day. The volume in the stock stood at 1.4 lakh shares today, compared to the daily average of 6.21 lakh shares in last one month.

The benchmark June futures contract for the stock is quoting at Rs 6597.5, down 0.78% on the day. Divis Laboratories Ltd jumped 52.04% in last one year as compared to a 6.22% rally in NIFTY and a 13.43% spurt in the Nifty Pharma index.

The PE of the stock is 79.46 based on TTM earnings ending March 25.

Powered by Capital Market - Live News

Divis Laboratories has entered into a long term manufacturing and supply agreement with a global pharma company.

Under this agreement, the Company will be manufacturing and supplying advanced intermediates as per the commercial terms agreed between the parties.

The Company expects meaningful revenue contribution from this long-term agreement.

Cost of capacity addition for manufacturing under this agreement is estimated to be Rs.650-750 crore, which will be funded from the capacity reservation advance proposed to be paid by the customer phase wise under this Agreement.

Powered by Capital Market - Live News

As part of the agreement, Divis will manufacture and supply advanced pharmaceutical intermediates to the global partner. The company has stated that the contract is expected to contribute meaningfully to its revenue over the long term.

To support the execution of this deal, Divis plans to invest between Rs 650 crore and Rs 750 crore to expand its manufacturing capacity. This investment will be funded through capacity reservation advances that will be paid in phases by the customer.

Divis Laboratories believes the partnership will not only ensure a reliable supply chain for the customer but also allow the company to strengthen its foothold in the custom synthesis space.

The company clarified that the deal does not involve any share exchange or related party transactions. There is no involvement of the promoter group or affiliated companies in the agreement.

Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients. The company's consolidated net profit jumped 23.04% to Rs 662 crore while revenue from operations grew by 12.24% to Rs 2,585 crore in Q4 March 2025 over Q4 March 2024.

Powered by Capital Market - Live News